Description: We are a biotech company fighting cancer
cancer (3276) oncology (581) immunotherapy (105) colorectal cancer (98) translational medicine (21) glioblastoma multiforme (17) therapeutic vaccine (7) hpv-associated cancer (5) oncolytic virus (5) german cancer research center (dkfz)
PLEASE NOTE:
This website is currently under complete revision, also to demonstrate new positive clinical data (November 2022).
ORYX’ development strategy bridges the gap between academic research and the pharmaceutical industry for new cancer therapies. Today, the company is developing three clinical cancer immunotherapy projects in indications with high unmet medical need. ORYX is the exclusive licensee of premier cancer immunotherapy substances from the German Cancer Research Center (DKFZ) and the University of Heidelberg. The Company has established close collaborations with DKFZ, Heidelberg University Hospital, National Center